dipyridamole has been researched along with Adenocarcinoma in 13 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 6.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "(1) To determine the toxicity of an intensified postoperative adjuvant regimen for periampullary adenocarcinoma (pancreatic and nonpancreatic) utilizing concurrent 5-fluorouracil (5-FU), leucovorin (LV), dipyridamole (DPM), and mitomycin-C (MMC) combined with split-course locoregional external beam radiotherapy (EBRT) to 50 Gy." | 3.70 | Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Donehower, RC; Grochow, LB; Hruban, RH; Hurwitz, H; Jaffee, EM; Korman, LT; Lillemoe, KD; O'Reilly, S; Yeo, CJ; Zahurek, ML, 2000) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 2.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "Dipyridamole (DIP) is a vasodilator and antithrombotic drug." | 1.51 | Dipyridamole impairs autophagic flux and exerts antiproliferative activity on prostate cancer cells. ( Guma, FT; Ilha, M; Lenz, G; Onzi, GR; Pereira, LC; Rohden, F; Thomé, MP; Wink, MR, 2019) |
| " In mouse hepatoma H22 model, the triple drug combination showed synergistic and highly potent antitumor efficacy." | 1.40 | A multifunctional drug combination shows highly potent therapeutic efficacy against human cancer xenografts in athymic mice. ( Li, Y; Liu, XJ; Wu, SY; Zhen, YS; Zheng, YB, 2014) |
| "The use of neoadjuvant chemotherapy for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors, especially for patients with Stage IV b (Japan criteria)." | 1.32 | [Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics]. ( Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S, 2004) |
| "Determined by clonogenic assay in human colon cancer HT-29 cells, the cell survivals for AZT, 10 microM, dipyridamole, 5 microM, and methotrexate (MTX), 0." | 1.28 | Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. ( Taniki, T; Weber, G; Zhen, YS, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thomé, MP | 1 |
| Pereira, LC | 1 |
| Onzi, GR | 1 |
| Rohden, F | 1 |
| Ilha, M | 1 |
| Guma, FT | 1 |
| Wink, MR | 1 |
| Lenz, G | 1 |
| Liu, XJ | 1 |
| Zheng, YB | 1 |
| Li, Y | 1 |
| Wu, SY | 1 |
| Zhen, YS | 2 |
| Taoka, H | 1 |
| Hirano, H | 1 |
| Mitsui, Y | 1 |
| Umino, W | 1 |
| Nobuoka, Y | 1 |
| Yamashita, M | 1 |
| Tanigawa, K | 1 |
| Yoshimine, S | 1 |
| Imai, T | 1 |
| Kadowaki, S | 1 |
| Miyashita, K | 1 |
| Ikuma, H | 1 |
| Nakamura, T | 1 |
| Murata, T | 1 |
| Isacoff, WH | 1 |
| Bendetti, JK | 1 |
| Barstis, JJ | 1 |
| Jazieh, AR | 1 |
| Macdonald, JS | 1 |
| Philip, PA | 1 |
| Barberi-Heyob, M | 1 |
| Griffon, G | 1 |
| Merlin, JL | 1 |
| Weber, B | 1 |
| Köhne, CH | 1 |
| Wilke, H | 1 |
| Schöffski, P | 1 |
| Schmoll, HJ | 1 |
| Berti, E | 1 |
| Carrara, M | 1 |
| Ragazzi, E | 1 |
| D'Ancona, S | 1 |
| Berti, T | 1 |
| Chakravarthy, A | 1 |
| Abrams, RA | 1 |
| Yeo, CJ | 1 |
| Korman, LT | 1 |
| Donehower, RC | 1 |
| Hruban, RH | 1 |
| Zahurek, ML | 1 |
| Grochow, LB | 1 |
| O'Reilly, S | 1 |
| Hurwitz, H | 1 |
| Jaffee, EM | 1 |
| Lillemoe, KD | 1 |
| Cameron, JL | 1 |
| Taniki, T | 1 |
| Weber, G | 1 |
| Lawrence, TS | 1 |
| Heimburger, DK | 1 |
| Shewach, DS | 1 |
| Lönn, U | 1 |
| Lönn, S | 1 |
| Nylen, U | 1 |
| Winblad, G | 1 |
| Chow, S | 1 |
| Roscoe, J | 1 |
| Cattran, DC | 1 |
| Wadler, S | 1 |
| Subar, M | 1 |
| Green, MD | 1 |
| Wiernik, PH | 1 |
| Muggia, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma[NCT00003018] | Phase 2 | 54 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dipyridamole and Adenocarcinoma
| Article | Year |
|---|---|
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin | 1996 |
1 trial available for dipyridamole and Adenocarcinoma
| Article | Year |
|---|---|
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipy | 2007 |
11 other studies available for dipyridamole and Adenocarcinoma
| Article | Year |
|---|---|
Dipyridamole impairs autophagic flux and exerts antiproliferative activity on prostate cancer cells.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Agents; Autophagosomes; Autophagy; Cell Divis | 2019 |
A multifunctional drug combination shows highly potent therapeutic efficacy against human cancer xenografts in athymic mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Wester | 2014 |
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2004 |
Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cis | 1993 |
A comparison of the modulation of antiblastics cytotoxicity by verapamil and dipyridamole in a human colon carcinoma cell line.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter | 1999 |
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2000 |
Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dipyridamole; DNA Replic | 1992 |
The effects of leucovorin and dipyridamole on fluoropyrimidine-induced radiosensitization.
Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Dipyridamole; DNA Repair; DNA, Neoplas | 1991 |
5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole.
Topics: Adenocarcinoma; Colonic Neoplasms; Dipyridamole; DNA; DNA Damage; Floxuridine; Fluorouracil; Humans; | 1989 |
Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Arginine; Argininosuccinic Ac | 1986 |
Phase II trial of oral methotrexate and dipyridamole in colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Colonic Neoplasms; Dipyridamole; Drug Evaluation; Drug T | 1987 |